Analysts Expect Neogen Co. (NASDAQ:NEOG) to Post $0.30 EPS
Equities analysts predict that Neogen Co. (NASDAQ:NEOG) will post earnings of $0.30 per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Neogen’s earnings. The highest EPS estimate is $0.30 and the lowest is $0.29. Neogen also posted earnings per share of $0.30 during the same quarter last year. The business is scheduled to report its next earnings report on Tuesday, July 28th.
On average, analysts expect that Neogen will report full year earnings of $1.11 per share for the current year, with EPS estimates ranging from $1.11 to $1.12. For the next year, analysts expect that the business will report earnings of $1.23 per share, with EPS estimates ranging from $1.21 to $1.26. Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Neogen.
NEOG has been the subject of several recent analyst reports. Zacks Investment Research lowered shares of Neogen from a “hold” rating to a “sell” rating and set a $64.00 price objective for the company. in a research note on Monday, March 2nd. TheStreet raised shares of Neogen from a “c” rating to a “b-” rating in a research report on Monday, May 11th. Finally, BidaskClub raised shares of Neogen from a “hold” rating to a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $76.67.
In related news, Director James L. Herbert sold 20,000 shares of the business’s stock in a transaction on Friday, April 3rd. The shares were sold at an average price of $63.16, for a total value of $1,263,200.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director James L. Herbert sold 19,368 shares of the business’s stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $66.13, for a total transaction of $1,280,805.84. Following the completion of the transaction, the director now owns 21,872 shares of the company’s stock, valued at $1,446,395.36. The disclosure for this sale can be found here. Insiders sold a total of 40,253 shares of company stock worth $2,600,646 over the last ninety days. Insiders own 1.70% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of NEOG. First Trust Advisors LP acquired a new position in shares of Neogen in the 4th quarter valued at $1,588,000. Victory Capital Management Inc. lifted its stake in shares of Neogen by 7.5% in the 4th quarter. Victory Capital Management Inc. now owns 7,463 shares of the company’s stock valued at $487,000 after purchasing an additional 518 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Neogen by 4.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 357,358 shares of the company’s stock valued at $23,322,000 after purchasing an additional 16,087 shares during the period. Aviva PLC acquired a new position in shares of Neogen in the 4th quarter valued at $1,923,000. Finally, Bank of Montreal Can lifted its stake in shares of Neogen by 8.3% in the 4th quarter. Bank of Montreal Can now owns 17,452 shares of the company’s stock valued at $1,139,000 after purchasing an additional 1,337 shares during the period. Hedge funds and other institutional investors own 92.96% of the company’s stock.
Neogen Company Profile
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment primarily offers diagnostic test kits and complementary to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells.
Recommended Story: Certificate of Deposit (CD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.